A patient-facing voice-based conversational artificial intelligence (VBAI) application that provided autonomous basal insulin titration has been found to improve time to optimal insulin dosing, insulin adherence, and glycemic control among adults with Type 2 diabetes.
The trial was conducted amongst 32 adults with Type 2 diabetes at four primary care clinics from March 2021 to December 2022, and is believed to be the first time that VBAI has been used to autonomously adjust medication doses.
The study found that: the time to optimal insulin dose was 15 days with the VBAI app, compared to 56 days with standard care; insulin adherence was 82.9% with the VBAI app, compared to 50.2% with standard care; glycemic control was achieved by 81.3% of participants using the VBAI app, compared to 25% of those receiving standard care; and average fasting glucose levels dropped by 45.9 mg/dL with VBAI but increased by 23.0 mg/dL with standard care.
The study authors commented that, “These findings suggest that digital health tools can be useful for medication titration and that voice user interfaces can be effective for patient facing digital technologies.”
To find out more, CLICK HERE.
